Stephen Ewald Sells 15,230 Shares of Medpace (NASDAQ:MEDP) Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) General Counsel Stephen Ewald sold 15,230 shares of the business’s stock in a transaction dated Monday, October 27th. The shares were sold at an average price of $598.85, for a total value of $9,120,485.50. Following the completion of the transaction, the general counsel directly owned 13,343 shares in the company, valued at $7,990,455.55. This represents a 53.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Medpace Price Performance

Shares of NASDAQ:MEDP opened at $580.37 on Friday. The company has a market capitalization of $16.35 billion, a price-to-earnings ratio of 40.59, a P/E/G ratio of 2.67 and a beta of 1.40. The business’s 50-day moving average is $513.09 and its 200-day moving average is $400.10. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $625.00.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, October 22nd. The company reported $3.86 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.36. The business had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm’s revenue for the quarter was up 23.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.01 earnings per share. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. GAMMA Investing LLC raised its position in Medpace by 37.1% in the 1st quarter. GAMMA Investing LLC now owns 307 shares of the company’s stock valued at $94,000 after buying an additional 83 shares during the last quarter. Smith Group Asset Management LLC grew its stake in shares of Medpace by 7.3% in the 1st quarter. Smith Group Asset Management LLC now owns 79,694 shares of the company’s stock worth $24,282,000 after acquiring an additional 5,436 shares in the last quarter. Novem Group grew its stake in shares of Medpace by 35.3% in the 1st quarter. Novem Group now owns 2,924 shares of the company’s stock worth $891,000 after acquiring an additional 763 shares in the last quarter. Teacher Retirement System of Texas grew its stake in shares of Medpace by 2.0% in the 1st quarter. Teacher Retirement System of Texas now owns 7,424 shares of the company’s stock worth $2,262,000 after acquiring an additional 144 shares in the last quarter. Finally, Meritage Portfolio Management grew its stake in shares of Medpace by 10.5% in the 1st quarter. Meritage Portfolio Management now owns 3,547 shares of the company’s stock worth $1,081,000 after acquiring an additional 336 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. TD Cowen increased their target price on shares of Medpace from $356.00 to $462.00 and gave the stock a “sell” rating in a research note on Friday, October 24th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Medpace in a report on Wednesday, October 8th. Mizuho boosted their target price on Medpace from $575.00 to $655.00 and gave the company an “outperform” rating in a research report on Friday, October 24th. Barclays raised their price objective on Medpace from $425.00 to $485.00 and gave the company an “underweight” rating in a research note on Friday, October 24th. Finally, Rothschild & Co Redburn cut Medpace from a “buy” rating to a “neutral” rating and raised their price objective for the company from $342.00 to $474.00 in a research note on Wednesday, September 3rd. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have assigned a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, Medpace currently has a consensus rating of “Hold” and an average target price of $475.90.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.